A healthcare system's pharmacy and therapeutics committee is reviewing a recently publishe… — USMLE Step 3

A healthcare system's pharmacy and therapeutics committee is reviewing a recently published multi-center, randomized, double-blind, placebo-controlled trial. The trial evaluated the efficacy and safety of a novel oral anticoagulant for stroke prevention in patients with non-valvular atrial fibrillation. The committee is determining whether to add this medication to their preferred formulary. The trial followed participants for a median of $2$ years. A summary table from the publication is provided below:

Clinical Endpoint	Novel Drug ( $n=5,000$ )	Placebo ( $n=5,000$ )	Hazard Ratio ( $95\%$ CI)
Ischemic Stroke	$150$ ( $3.0\%$ )	$250$ ( $5.0\%$ )	$0.59$ ( $0.45-0.78$ )
Major Gastrointestinal Bleeding	$200$ ( $4.0\%$ )	$50$ ( $1.0\%$ )	$4.08$ ( $2.55-6.52$ )
All-cause Mortality	$400$ ( $8.0\%$ )	$420$ ( $8.4\%$ )	$0.95$ ( $0.80-1.12$ )

The chief medical officer requests a population-level impact analysis. If the healthcare system immediately switches $2,500$ similar patients from placebo to the novel drug, which of the following is the most accurate projected clinical impact over a $2$ -year period based on these trial results?

Prevention of $50$ ischemic strokes and an increase of $75$ major gastrointestinal bleeding eventsAnswer
B
Prevention of $50$ ischemic strokes and a statistically significant reduction in all-cause mortality
C
The reduction in ischemic strokes is entirely explained by confounding, as the overall mortality rate did not improve
D
The positive predictive value of the drug is nullified because the absolute risk increase for bleeding exceeds the absolute risk reduction for stroke
E
The drug is absolutely contraindicated in this population due to the $300\%$ relative risk increase in major gastrointestinal bleeding

Answer

Prevention of 50 ischemic strokes and an increase of 75 major gastrointestinal bleeding events

The correct answer accurately calculates the absolute population impact using the raw event rates provided in the table. The Absolute Risk Reduction (ARR) for ischemic stroke is

5.0\% - 3.0\% = 2.0\%

. Over

2,500

patients, this prevents

50

strokes (

2,500 \times 0.02

). The Absolute Risk Increase (ARI) for major gastrointestinal bleeding is

4.0\% - 1.0\% = 3.0\%

. Over

2,500

patients, this causes

75

additional bleeding events (

2,500 \times 0.03

). Translating relative metrics (like Hazard Ratios) into absolute numbers is essential for population health management and shared decision-making.

Step-by-Step Solution

Calculate the Absolute Risk Reduction (ARR) for the primary efficacy endpoint (Ischemic Stroke).

\text{ARR} = \text{Placebo Rate} - \text{Drug Rate} = 5.0\% - 3.0\% = 2.0\%

(or

0.02

ARR determines the actual absolute percentage of patients spared from the adverse outcome when treated.

Apply the ARR to the target population of 2,500 patients to find the number of strokes prevented.

2,500 \times 0.02 = 50

ischemic strokes prevented.

Multiplying the ARR by the number of treated patients yields the projected population benefit.

Calculate the Absolute Risk Increase (ARI) for the primary safety endpoint (Major Gastrointestinal Bleeding).

\text{ARI} = \text{Drug Rate} - \text{Placebo Rate} = 4.0\% - 1.0\% = 3.0\%

(or

0.03

ARI determines the actual absolute percentage of patients who will suffer the adverse effect due to the treatment.

Apply the ARI to the target population of 2,500 patients to find the number of additional bleeds.

2,500 \times 0.03 = 75

additional major gastrointestinal bleeding events.

Multiplying the ARI by the number of treated patients yields the projected population harm.

Key Concept

Evaluating clinical impact requires calculating Absolute Risk Reduction (ARR) and Absolute Risk Increase (ARI) from trial event rates and applying them directly to the proposed population size.

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic